Thalia Herrera-Calvo

Thalia Herrera-Calvo

Auto-generated profile, based on publicly available information

Thalia Herrera-Calvo


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
APAlberto Polo-Barranco
Alberto Polo-Barranco
CRCarlos Rebolledo-Maldonado
Carlos Rebolledo-Maldonado
DBDayro Enrique Rodelo barrios
Dayro Enrique Rodelo barrios
JSJuan Solano-Ropero
Juan Solano-Ropero
VOValentina Rada Obeso
Valentina Rada Obeso
EOElber Luis Osorio-Rodriguez
Elber Luis Osorio-Rodriguez
Lipoprotein(a) [Lp(a)] is a predominantly genetic risk factor for atherosclerotic cardiovascular disease and calcified aortic valve disease (CAVD). In addition to its epidemiological and genetic association with aortic stenosis, Lp(a) transports oxidized phospholipids, lysophosphatidylcholine, and autotaxin, components capable of promoting inflammation, oxidative stress, and valvular fibrocalcifying remodeling. This review synthesizes the molecular, cellular, and clinical evidence linking Lp(a) to CAVD progression. Retention of Lp(a) and other apolipoprotein B-containing lipoproteins in the valvular matrix promotes endothelial activation, monocyte and macrophage recruitment, and the release of proinflammatory mediators. Oxidized phospholipids and the autotaxin-lysophosphatidic acid axis activate redox-dependent pathways and promote the transition of valvular interstitial cells to myofibroblastic and osteogenic phenotypes. These processes converge in alterations in cholesterol metabolism, the release of procalcifying extracellular vesicles, and hydroxyapatite nucleation. Genetic and imaging evidence support an association between elevated Lp(a), microcalcifying activity, and accelerated hemodynamic progression. Although anti-Lp(a) therapies substantially reduce plasma Lp(a) concentrations, their effect on valvular outcomes has not yet been demonstrated.

Verified
Journal Article
Open access
PDF file
APAlberto Polo-Barranco
Alberto Polo-Barranco
CRCarlos Rebolledo-Maldonado
Carlos Rebolledo-Maldonado
DBDayro Enrique Rodelo barrios
Dayro Enrique Rodelo barrios
JSJuan Solano-Ropero
Juan Solano-Ropero
VOValentina Rada Obeso
Valentina Rada Obeso
EOElber Luis Osorio-Rodriguez
Elber Luis Osorio-Rodriguez
Elevated plasma lipoprotein(a) [Lp(a)] levels represent a predominantly genetically determined risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease (CAVD). Mechanistically, Lp(a) transports oxidized phospholipids, lysophosphatidylcholine, and autotaxin, components capable of promoting inflammation, oxidative stress, and valvular fibrocalcific remodeling. This review synthesizes the molecular, cellular, and clinical evidence linking Lp(a) to CAVD progression. Retention of Lp(a) and other apolipoprotein B-containing lipoproteins in the valvular matrix promotes endothelial activation, recruitment of cells of the monocytic lineage, and the release of proinflammatory mediators. Oxidized phospholipids and the autotaxin–lysophosphatidic acid axis activate redox-dependent pathways and promote the transition of valvular interstitial cells toward myofibroblastic and/or osteogenic phenotypes. These processes converge in alterations in cholesterol metabolism, the release of procalcifying extracellular vesicles, and hydroxyapatite nucleation. Genetic and imaging evidence supports an association between elevated Lp(a), microcalcifying activity, and accelerated hemodynamic progression. Although anti-Lp(a) therapies substantially reduce plasma Lp(a) concentrations, their effect on valvular outcomes has not yet been demonstrated.